These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23087257)

  • 1. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
    Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
    Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
    Stresemann C; Lyko F
    Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
    Aparicio A; North B; Barske L; Wang X; Bollati V; Weisenberger D; Yoo C; Tannir N; Horne E; Groshen S; Jones P; Yang A; Issa JP
    Epigenetics; 2009 Apr; 4(3):176-84. PubMed ID: 19421002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
    Kaiser MF; Johnson DC; Wu P; Walker BA; Brioli A; Mirabella F; Wardell CP; Melchor L; Davies FE; Morgan GJ
    Blood; 2013 Jul; 122(2):219-26. PubMed ID: 23699600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
    Moreaux J; Bruyer A; Veyrune JL; Goldschmidt H; Hose D; Klein B
    Br J Haematol; 2014 Feb; 164(4):613-6. PubMed ID: 24224771
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation.
    Fabianowska-Majewska K; Wyczechowska D; Czyz M
    Adv Exp Med Biol; 2000; 486():343-7. PubMed ID: 11783512
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
    Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
    Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
    Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation and gene silencing in cancer.
    Baylin SB
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
    Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
    Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
    Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
    Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stress chaperones, mortalin, and pex19p mediate 5-aza-2' deoxycytidine-induced senescence of cancer cells by DNA methylation-independent pathway.
    Widodo N; Deocaris CC; Kaur K; Hasan K; Yaguchi T; Yamasaki K; Sugihara T; Ishii T; Wadhwa R; Kaul SC
    J Gerontol A Biol Sci Med Sci; 2007 Mar; 62(3):246-55. PubMed ID: 17389721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
    Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
    Lavelle D; DeSimone J; Hankewych M; Kousnetzova T; Chen YH
    Leuk Res; 2003 Nov; 27(11):999-1007. PubMed ID: 12859993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
    Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
    Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.
    Tsai HC; Li H; Van Neste L; Cai Y; Robert C; Rassool FV; Shin JJ; Harbom KM; Beaty R; Pappou E; Harris J; Yen RW; Ahuja N; Brock MV; Stearns V; Feller-Kopman D; Yarmus LB; Lin YC; Welm AL; Issa JP; Minn I; Matsui W; Jang YY; Sharkis SJ; Baylin SB; Zahnow CA
    Cancer Cell; 2012 Mar; 21(3):430-46. PubMed ID: 22439938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.